Preclinical results in small-cell lung cancer, colorectal cancer, and breast cancer suggest that vasculature normalization by inhibiting the VEGF/VEGFR pathway reprograms the immunosuppressive tumor microenvironment and enhances immunotherapy [177,178,179,180]. This evidence concerns the gene VEGFA and neoplasm.